View in EDS

Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.

Saved in:
Bibliographic Details
Title: Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.
Authors: Overgaard RV; Novo Nordisk A/S, Søborg, Denmark., Birkhan O; Novo Nordisk A/S, Søborg, Denmark., Rathor N; Novo Nordisk A/S, Søborg, Denmark., Sparsø T; Novo Nordisk A/S, Søborg, Denmark., Strathe A; Novo Nordisk A/S, Søborg, Denmark., Wharton S; University of Toronto, York University, McMaster University, Wharton Weight Management Clinic, Burlington, Ontario, Canada., Rubino D; Washington Center for Weight Management and Research, Arlington, Virginia, USA.
Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2026 Jul; Vol. 28 (7), pp. 5982-5991. Date of Electronic Publication: 2026 Apr 23.
Publication Type: Journal Article; Comparative Study
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42023428
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Overgaard+RV%22">Overgaard RV</searchLink>; Novo Nordisk A/S, Søborg, Denmark.<br /><searchLink fieldCode="AU" term="%22Birkhan+O%22">Birkhan O</searchLink>; Novo Nordisk A/S, Søborg, Denmark.<br /><searchLink fieldCode="AU" term="%22Rathor+N%22">Rathor N</searchLink>; Novo Nordisk A/S, Søborg, Denmark.<br /><searchLink fieldCode="AU" term="%22Sparsø+T%22">Sparsø T</searchLink>; Novo Nordisk A/S, Søborg, Denmark.<br /><searchLink fieldCode="AU" term="%22Strathe+A%22">Strathe A</searchLink>; Novo Nordisk A/S, Søborg, Denmark.<br /><searchLink fieldCode="AU" term="%22Wharton+S%22">Wharton S</searchLink>; University of Toronto, York University, McMaster University, Wharton Weight Management Clinic, Burlington, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Rubino+D%22">Rubino D</searchLink>; Washington Center for Weight Management and Research, Arlington, Virginia, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100883645%22">Diabetes, obesity & metabolism</searchLink> [Diabetes Obes Metab] 2026 Jul; Vol. 28 (7), pp. 5982-5991. <i>Date of Electronic Publication: </i>2026 Apr 23.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Comparative Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100883645 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1463-1326 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214628902%22">14628902 </searchLink><i>NLM ISO Abbreviation: </i>Diabetes Obes Metab <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42023428
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/dom.70769
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 5982
    Titles:
      – TitleFull: Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Overgaard RV
      – PersonEntity:
          Name:
            NameFull: Birkhan O
      – PersonEntity:
          Name:
            NameFull: Rathor N
      – PersonEntity:
          Name:
            NameFull: Sparsø T
      – PersonEntity:
          Name:
            NameFull: Strathe A
      – PersonEntity:
          Name:
            NameFull: Wharton S
      – PersonEntity:
          Name:
            NameFull: Rubino D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2026 Jul
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1463-1326
          Numbering:
            – Type: volume
              Value: 28
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Diabetes, obesity & metabolism
              Type: main
ResultId 1